How India Exports Ketoconazole to the World

In the United States, ketoconazole is approved for various formulations, including oral tablets and topical applications. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for ketoconazole tablets, indicating a competitive generic market. Notably, Novopharm Limited received approval for ketoconazole tablets under ANDA #74-971 on June 15, 1999.

The FDA has issued warnings regarding the risk of severe liver injury associated with oral ketoconazole. Consequently, its use is limited to specific indications where alternative treatments are unavailable or inappropriate. Topical formulations, such as shampoos and creams, are considered safer and remain widely used. Given the substantial number of active Indian exporters (446) supplying ketoconazole to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and post-market surveillance, is imperative to ensure market access and patient safety.

In July 2013, the European Medicines Agency (EMA) recommended the suspension of marketing authorizations for oral ketoconazole due to concerns over liver toxicity outweighing its benefits in treating fungal infections. (ema.europa.eu) However, recognizing its efficacy in treating Cushing's syndrome, the EMA granted marketing authorization for Ketoconazole HRA (now Ketoconazole Esteve) on November 19, 2014, specifically for this indication. (ema.europa.eu)

The United Kingdom, following EMA guidelines, has implemented similar regulatory measures. Manufacturers exporting ketoconazole to these markets must adhere to EU and UK GMP standards, ensuring product quality and safety. Additionally, obtaining marketing authorization from the EMA or the UK's Medicines and Healthcare products Regulatory Agency (MHRA) is essential for legal distribution within these regions.

Ketoconazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The WHO Prequalification Programme evaluates medicines to ensure they meet global standards for quality, safety, and efficacy. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is crucial for manufacturers aiming to supply ketoconazole to international markets.

In India, ketoconazole is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest updates, ketoconazole is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the quality of pharmaceutical exports.

The primary patents for ketoconazole have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has resulted in a decrease in prices and increased accessibility. However, manufacturers must remain vigilant regarding any new patents related to specific formulations or delivery methods that could impact market dynamics.

In March 2025, the NPPA conducted a review of antifungal medications, including ketoconazole, to assess market prices and ensure affordability for patients. While no immediate price controls were implemented, the NPPA emphasized the importance of monitoring price trends to prevent exorbitant pricing.

In January 2026, the EMA updated the product information for Ketoconazole Esteve, incorporating new safety data and reinforcing the need for regular liver function monitoring during treatment. (ema.europa.eu)

In February 2026, the FDA issued a safety communication highlighting the risk of drug interactions between ketoconazole and certain medications, advising healthcare providers to review patient medications thoroughly before prescribing ketoconazole.

In March 2026, the WHO released updated guidelines on the management of fungal infections, reaffirming the role of ketoconazole in specific cases while emphasizing the need for careful patient selection and monitoring due to potential adverse effects.

In April 2026, the CDSCO announced a crackdown on substandard antifungal medications, including ketoconazole, following reports of quality issues. Manufacturers were urged to adhere strictly to GMP standards to ensure product quality and patient safety.

These developments underscore the dynamic regulatory environment surrounding ketoconazole, highlighting the necessity for manufacturers and exporters to stay informed and compliant with evolving standards to maintain market access and ensure patient safety.

India's pharmaceutical industry, including the production of Ketoconazole, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact Indian API production. For instance, in June 2025, escalating military conflicts led to the closure of the Strait of Hormuz, a critical chokepoint for global energy and raw material supplies. This closure disrupted the supply of petrochemical feedstocks essential for pharmaceutical synthesis, causing delays and increased costs for Indian API manufacturers. (pharmasource.global)

To mitigate such risks, the Indian government has initiated the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, which are crucial for antibiotic production. These efforts are expected to reduce India's import dependence on key pharmaceutical ingredients by half.

The Ketoconazole export market from India exhibits a moderate level of supplier concentration. The top five exporters account for 55.5% of the total export value, with KUSUM HEALTHCARE PRIVATE LIMITED leading at 17.1%. While this concentration indicates a degree of market dominance by a few players, the presence of 446 active exporters suggests a relatively diversified supplier base. However, reliance on a limited number of key suppliers can pose risks, especially if any of these entities face operational disruptions.

The PLI scheme, launched by the Indian government, aims to enhance domestic manufacturing capabilities and reduce dependency on imports. By incentivizing local production of APIs and KSMs, the scheme seeks to diversify the supplier base and mitigate risks associated with supplier concentration. As of November 2024, the scheme has led to significant investments in domestic API production, with commitments exceeding initial targets.

Geopolitical tensions have significantly impacted global supply chains, including the pharmaceutical sector. In February 2026, the closure of the Strait of Hormuz due to military conflicts disrupted the supply of raw materials and increased transportation costs. This chokepoint is vital for the transit of petrochemical feedstocks essential for API production.

Additionally, instability in the Red Sea and the Suez Canal has forced shipping companies to reroute vessels around the Cape of Good Hope, adding 10 to 14 days to transit times and increasing fuel costs. These disruptions have led to delays in the delivery of pharmaceuticals and raw materials, affecting global supply chains.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different geographic regions to reduce dependency on a single country.

• Enhance Domestic Production: Continue to invest in domestic manufacturing capabilities for APIs and KSMs through initiatives like the PLI scheme to strengthen supply chain resilience.

• Develop Strategic Reserves: Establish reserves of critical raw materials and APIs to buffer against supply chain disruptions.

• Strengthen Supplier Relationships: Foster strong partnerships with multiple suppliers to ensure flexibility and reliability in sourcing.

• Monitor Geopolitical Developments: Implement robust monitoring systems to anticipate and respond to geopolitical events that may impact supply chains.

RISK_LEVEL: MEDIUM